All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2024-07-31.
From the record
China SXT Pharmaceuticals, Inc.'s filings since 2017 show 3 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2024-07-31) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-16.7% a year over 4 filed years; profitable in 0 of 4.
From the record
China SXT Pharmaceuticals, Inc.'s 4 filed years say what it did: revenue went from $2 million in fiscal 2023 to $1 million in fiscal 2026, down 16.7% a year; it rose in 0 of 3 years; the deepest fall was 42% from fiscal 2023 to fiscal 2026; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 0.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: China SXT Pharmaceuticals, Inc.'s shareholder treatment is put at 0.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 2% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -21%: lost 21¢ per shareholder dollar. Leverage 15%: owes 15¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2026-03-31, China SXT Pharmaceuticals, Inc. lost about 21 cents for every dollar of shareholders' money, and gross profitability: its products earned about 1 cents per dollar of everything the company owns. Leverage: it owed about 15 cents per dollar of assets, and net share issuance: its share count grew 7062.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 27% of 315 in its family; net margin -545.2%.
From the record
China SXT Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $1 million in fiscal 2026 ranks in the bottom 23% by size; a net margin of -545.2% ranks in the bottom 36%; revenue growth of -16.7% a year over the last 3 filed years ranks in the bottom 22% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 5.0/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: China SXT Pharmaceuticals, Inc.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-04-27 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 44% of 273 in its family for room to expand.
From the record
China SXT Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $28 million against debt of $644 thousand leaves 79.2% of its assets as net cash, top 19% of its family; cash from operations less capital spending is -353% of revenue (bottom 39%); a gross margin of 21.9% (bottom 12%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 27% of 306 in its family for growth drivers.
From the record
China SXT Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2026: revenue grew -16.7% a year over the last three filed years against -16.7% over all 4, speeding up (top 40% of its family); the newest year grew -34.6% (bottom 23%); research spending grew -29.1% a year (bottom 13%); capital spending grew -60.5% a year (bottom 13%) (its annual reports). China SXT Pharmaceuticals, Inc. reported 4 product lines in fiscal 2026: Regular TCMP at $1 million (95%), Advanced TCMP at $50 thousand (4%), Others at $7 thousand (1%), and 1 more; 0 of 4 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 23% of 233 in its family for expectations against reality.
From the record
China SXT Pharmaceuticals, Inc.'s newest year against its own record: revenue of $1 million in fiscal 2026 came in 30.4% below the $2 million its prior three years' pace pointed to (bottom 26% of its family); net income of $6 million against a prior three-year average of $4 million (bottom 26%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 17%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made